NCT05949281View on ClinicalTrials.gov

Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 29, 2023

Primary Completion Date

June 15, 2026

Study Completion Date

June 15, 2026

Conditions
Type 1 DiabetesCardiovascular DiseasesChronic Inflammation
Interventions
DRUG

Colchicine 0.5 MG Oral Tablet

Colchicine 0.5 mg once-daily

DRUG

Placebo

Placebo tablet once-daily

Trial Locations (1)

2900

Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup

Sponsors
All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

Asger Lund, MD

OTHER